<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IDAMYCIN PFS- idarubicin hydrochloride solution </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>Idamycin PFS<span class="Sup">®</span><br> idarubicin hydrochloride injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNINGS</span></h1>
<ol>
<li>IDAMYCIN PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> can occur if there is <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration.</li>
<li>As is the case with other anthracyclines the use of IDAMYCIN PFS can cause myocardial toxicity leading to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre-existing cardiac disease.</li>
<li>As is usual with antileukemic agents, severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurs when IDAMYCIN PFS is used at effective therapeutic doses.</li>
<li>It is recommended that IDAMYCIN PFS be administered only under the supervision of a physician who is experienced in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>Dosage should be reduced in patients with impaired hepatic or renal function. (See <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-<span class="Italics">lyxo</span>-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-<span class="Italics">cis</span>). The structural formula is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-01.jpg"></div>
<p>C<span class="Sub">26</span> H<span class="Sub">27</span> NO<span class="Sub">9</span> ∙HCL        M.W. 533.96</p>
<p>IDAMYCIN PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.</p>
<p>Each mL contains Idarubicin HCL, USP 1 mg and the following inactive ingredients: Glycerin, USP 25 mg and Water for Injection, USP q.s. Hydrochloric Acid, NF is used to adjust the pH to a target of 3.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>General Pharmacokinetics</h3>
<p class="First">Pharmacokinetic studies have been performed in adult <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients with normal renal and hepatic function following intravenous administration of 10 to 12 mg/m<span class="Sup">2</span> of idarubicin daily for 3 to 4 days as a single agent or combined with cytarabine. The plasma concentrations of idarubicin are best described by a two or three compartment open model. The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine. The elimination of the primary active metabolite, idarubicinol, is considerably slower than that of the parent drug with an estimated mean terminal half-life that exceeds 45 hours; hence, its plasma levels are sustained for a period greater than 8 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The disposition profile shows a rapid distributive phase with a very high volume of distribution presumably reflecting extensive tissue binding. Studies of cellular (nucleated blood and bone marrow cells) drug concentrations in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients have shown that peak cellular idarubicin concentrations are reached a few minutes after injection. Concentrations of idarubicin and idarubicinol in nucleated blood and bone marrow cells are more than a hundred times the plasma concentrations. Idarubicin disappearance rates in plasma and cells were comparable with a terminal half-life of about 15 hours. The terminal half-life of idarubicinol in cells was about 72 hours. The extent of drug and metabolite accumulation predicted in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients for Days 2 and 3 of dosing, based on the mean plasma levels and half-life obtained after the first dose, is 1.7- and 2.3-fold, respectively, and suggests no change in kinetics following a daily × 3 regimen. The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies. The binding is concentration independent. The plasma clearance is twice the expected hepatic plasma flow indicating extensive extrahepatic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">The primary active metabolite formed is idarubicinol. As idarubicinol has cytotoxic activity, it presumably contributes to the effects of idarubicin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">Idarubicin studies in pediatric <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients, at doses of 4.2 to 13.3 mg/m<span class="Sup">2</span>/day × 3, suggest dose independent kinetics. There is no difference between the half-lives of the drug following daily × 3 or weekly × 3 administration. Cerebrospinal fluid (CSF) levels of idarubicin and idarubicinol were measured in pediatric <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients treated intravenously. Idarubicin was detected in 2 of 21 CSF samples (0.14 and 1.57 ng/mL), while idarubicinol was detected in 20 of these 21 CSF samples obtained 18 to 30 hours after dosing (mean = 0.51 ng/mL; range, 0.22 to 1.05 ng/mL). The clinical relevance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">The pharmacokinetics of idarubicin have not been evaluated in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. It is expected that in patients with moderate or severe hepatic dysfunction, the metabolism of idarubicin may be impaired and lead to higher systemic drug levels. The disposition of idarubicin may be also affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, a dose reduction should be considered in patients with hepatic and/or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">No formal drug interaction studies have been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CS"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Four prospective randomized studies, three U.S. and one Italian, have been conducted to compare the efficacy and safety of idarubicin (IDR) to that of daunorubicin (DNR), each in combination with cytarabine as induction therapy in previously untreated adult patients with <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> (AML). These data are summarized in the following table and demonstrate significantly greater complete remission rates for the IDR regimen in two of the three U.S. studies and significantly longer overall survival for the IDR regimen in two of the three U.S. studies. </p>
<table width="100%">
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2">Induction<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="center" colspan="4"></th>
</tr>
<tr>
<th align="left"></th>
<th align="center" colspan="2">Regimen Dose</th>
<th align="center" colspan="2">Complete</th>
<th align="center" colspan="2">Median Survival</th>
</tr>
<tr>
<th align="left"></th>
<th align="center" colspan="2">in mg/m<span class="Sup">2</span>-</th>
<th align="center" colspan="2">Remission Rate,</th>
<th align="center" colspan="2">(Days)</th>
</tr>
<tr>
<th align="left"></th>
<th align="center" colspan="2"><span class="Underline">Daily × 3 Days</span></th>
<th align="center" colspan="2"><span class="Underline">All Pts Randomized</span></th>
<th align="center" colspan="2"><span class="Underline">All Pts Randomized</span></th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">IDR</th>
<th align="center">DNR</th>
<th align="center">IDR</th>
<th align="center">DNR</th>
<th align="center">IDR</th>
<th align="center">DNR</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Patients who had persistent <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> after the first induction course received a second course</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Memorial Sloan Kettering Cancer Center</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Cytarabine 25 mg/m<span class="Sup">2</span> bolus IV followed by 200 mg/m<span class="Sup">2</span> daily × 5 days by continuous infusion</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Overall p &lt; 0.05, unadjusted for prognostic factors or multiple endpoints</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Southeastern Cancer Study Group</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Cytarabine 100 mg/m<span class="Sup">2</span> daily × 7 days by continuous infusion</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Þ</a></dt>
<dd>Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Underline">U.S. (IND Studies)</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">1. MSKCC<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">12<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">50<a href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">51/65<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">38/65</td>
<td align="center">508<a href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">435</td>
</tr>
<tr>
<td align="left">(Age ≤ 60 years)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">(78%)</td>
<td align="center">(58%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">2. SEG<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td align="center">12<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">45<a href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">76/111<a href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">65/119</td>
<td align="center">328</td>
<td align="center">277</td>
</tr>
<tr>
<td align="left">(Age ≥ 15 years)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">(69%)</td>
<td align="center">(55%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">3. U.S. Multicenter</td>
<td align="center">13<a href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">45<a href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">68/101</td>
<td align="center">66/113</td>
<td align="center">393<a href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">281</td>
</tr>
<tr>
<td align="left">(Age ≥ 18 years)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">(67%)</td>
<td align="center">(58%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Underline">Foreign (non-IND study)</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">GIMEMA<a name="footnote-reference-7" href="#footnote-7" class="Sup">Þ</a>
</td>
<td align="center">12<a href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">45<a href="#footnote-6" class="Sup">#</a>
</td>
<td align="center">49/124</td>
<td align="center">49/125</td>
<td align="center">87</td>
<td align="center">169</td>
</tr>
<tr class="Last">
<td align="left">(Age ≥ 55 years)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">(40%)</td>
<td align="center">(39%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>There is no consensus regarding optional regimens to be used for consolidation; however, the following consolidation regimens were used in U.S. controlled trials. Patients received the same anthracycline for consolidation as was used for induction.</p>
<p>Studies 1 and 3 utilized 2 courses of consolidation therapy consisting of idarubicin 12 or 13 mg/m<span class="Sup">2</span> daily for 2 days, respectively (or DNR 50 or 45 mg/m<span class="Sup">2</span> daily for 2 days), and cytarabine, either 25 mg/m<span class="Sup">2</span> by IV bolus followed by 200 mg/m<span class="Sup">2</span> daily by continuous infusion for 4 days (Study 1), or 100 mg/m<span class="Sup">2</span> daily for 5 days by continuous infusion (Study 3). A rest period of 4 to 6 weeks is recommended prior to initiation of consolidation and between the courses. Hematologic recovery is mandatory prior to initiation of each consolidation course.</p>
<p>Study 2 utilized 3 consolidation courses, administered at intervals of 21 days or upon hematologic recovery. Each course consisted of idarubicin 15 mg/m<span class="Sup">2</span> IV for 1 dose (or DNR 50 mg/m<span class="Sup">2</span> IV for 1 dose), cytarabine 100 mg/m<span class="Sup">2</span> every 12 hours for 10 doses and 6-thioguanine 100 mg/m<span class="Sup">2</span> orally for 10 doses. If severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred, subsequent courses were given with 25% reduction in the doses of all drugs. In addition, this study included 4 courses of maintenance therapy (2 days of the same anthracycline as was used in induction and 5 days of cytarabine).</p>
<p>Toxicities and duration of <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> were similar during induction on the 2 arms in the U.S. studies except for an increase in <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> on the IDR arm in one study. During consolidation, duration of <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> on the IDR arm was longer in all three studies and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> was more frequent in two studies. During consolidation, transfusion requirements were higher on the IDR arm in the two studies in which they were tabulated, and patients on the IDR arm in Study 3 spent more days on IV antibiotics (Study 3 used a higher dose of idarubicin).</p>
<p>The benefit of consolidation and maintenance therapy in prolonging the duration of remission and survival is not proven.</p>
<p>Intensive maintenance with idarubicin is not recommended in view of the considerable toxicity (including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in remission) experienced by patients during the maintenance phase of Study 2.</p>
<p>A higher induction <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> rate was noted in patients on the IDR arm in the Italian trial. Since this was not noted in patients of similar age in the U.S. trials, one may speculate that it was due to a difference in the level of supportive care.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">IDAMYCIN PFS Injection in combination with other approved antileukemic drugs is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Idarubicin is intended for administration under the supervision of a physician who is experienced in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> chemotherapy.</p>
<p>Idarubicin is a potent bone marrow suppressant. Idarubicin should not be given to patients with pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> will occur in all patients given a therapeutic dose of this agent for induction, consolidation or maintenance. Careful hematologic monitoring is required. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported during the period of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Facilities with laboratory and supportive resources adequate to monitor drug tolerability and protect and maintain a patient compromised by <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span> should be available. It must be possible to treat rapidly and completely a severe hemorrhagic condition and/or a severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Pre-existing heart disease and previous therapy with anthracyclines at high cumulative doses or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity and the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with idarubicin.</p>
<p>Myocardial toxicity as manifested by potentially fatal <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, acute life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or other cardiomyopathies may occur following therapy with idarubicin. Appropriate therapeutic measures for the management of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and/or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> are indicated.</p>
<p>Cardiac function should be carefully monitored during treatment in order to minimize the risk of cardiac toxicity of the type described for other anthracycline compounds. The risk of such myocardial toxicity may be higher following concomitant or previous radiation to the mediastinal-pericardial area or in patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, leukemic <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span> and/or <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, active or dormant cardiovascular disease, previous therapy with other anthracyclines or anthracenediones, and concomitant use of drugs with the ability to suppress cardiac contractility or cardiotoxic drugs (e.g., trastuzumab, cyclophosphamide and paclitaxel). Do not administer idarubicin with other cardiotoxic agents unless the patient's cardiac function is monitored frequently. Patients receiving anthracyclines after stopping treatment with other cardiotoxic agents, especially those with long half-lives, may also be at an increased risk of developing cardiotoxicity. Avoid the use of anthracycline-based therapy for at least 5 half-lives after discontinuation of the cardiotoxic agent. If anthracyclines are used before this time, carefully monitor the cardiac function. While there are no reliable means for predicting <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> induced by anthracyclines is usually associated with a decrease of the left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) from pretreatment baseline values.</p>
<p>Since hepatic and/or renal function impairment can affect the disposition of idarubicin, liver and kidney function should be evaluated with conventional clinical laboratory tests (using serum bilirubin and serum creatinine as indicators) prior to and during treatment. In a number of Phase III clinical trials, treatment was not given if bilirubin and/or creatinine serum levels exceeded 2 mg%. However, in one Phase III trial, patients with bilirubin levels between 2.6 and 5 mg% received the anthracycline with a 50% reduction in dose. Dose reduction of idarubicin should be considered if the bilirubin and/or creatinine levels are above the normal range. (See <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">Idarubicin was embryotoxic and teratogenic in the rat at a dose of 1.2 mg/m<span class="Sup">2</span>/day or one tenth the human dose, which was nontoxic to dams. Idarubicin was embryotoxic but not teratogenic in the rabbit even at a dose of 2.4 mg/m<span class="Sup">2</span>/day or two tenths the human dose, which was toxic to dams. There is no conclusive information about idarubicin adversely affecting human fertility or causing teratogenesis. There has been one report of a fetal fatality after maternal exposure to idarubicin during the second trimester.</p>
<p>There are no adequate and well-controlled studies in pregnant women. If idarubicin is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Therapy with idarubicin requires close observation of the patient and careful laboratory monitoring. <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> secondary to rapid lysis of leukemic cells may be induced. Appropriate measures must be taken to prevent <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and to control any systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before beginning therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of idarubicin can cause severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> may occur with or without an accompanying <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> even if blood returns well on <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of the infusion needle. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occur the injection or infusion should be terminated immediately and restarted in another vein. (See <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Frequent complete blood counts and monitoring of hepatic and renal function tests are recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Formal long-term carcinogenicity studies have not been conducted with idarubicin. Idarubicin and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models (including bacterial systems, mammalian cells in culture and female Sprague-Dawley rats).</p>
<p>In male dogs given 1.8 mg/m<span class="Sup">2</span>/day 3 times/week (about one seventh the weekly human dose on a mg/m<span class="Sup">2</span> basis) for 13 weeks, or 3 times the human dose, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> was observed with inhibition of spermatogenesis and sperm maturation with few or no mature sperm. These effects were not readily reversed after a recovery of 8 weeks.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">(See <a href="#WARNINGS">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from idarubicin, mothers should discontinue nursing prior to taking this drug.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Patients over 60 years of age who were undergoing induction therapy experienced <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and asymptomatic declines in LVEF more frequently than younger patients (see <a href="#AR">ADVERSE REACTIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Approximately 550 patients with AML have received idarubicin in combination with cytarabine in controlled clinical trials worldwide. In addition, over 550 patients with <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> have been treated in uncontrolled trials utilizing idarubicin as a single agent or in combination. The table below lists the adverse experiences reported in U.S.</p>
<p>Study 2 (see <a href="#CS">CLINICAL STUDIES</a>) and is representative of the experiences in other studies. These adverse experiences constitute all reported or observed experiences, including those not considered to be drug related. Patients undergoing induction therapy for AML are seriously ill due to their disease, are receiving multiple transfusions, and concomitant medications including potentially toxic antibiotics and antifungal agents. The contribution of the study drug to the adverse experience profile is difficult to establish.</p>
<table width="90%">
<col align="left" valign="top" width="36%">
<col align="center" valign="top" width="32%">
<col align="center" valign="top" width="32%">
<thead>
<tr class="First">
<th align="left"><span class="Underline">Induction Phase</span></th>
<th align="center" colspan="2"><span class="Underline">Percentage of Patients</span></th>
</tr>
<tr>
<th align="left"></th>
<th align="center">IDR</th>
<th align="center">DNR</th>
</tr>
<tr class="Last">
<th align="left">Adverse Experiences</th>
<th align="center">(N=110)</th>
<th align="center">(N=118)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center">95%</td>
<td align="center">97%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">82%</td>
<td align="center">80%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair Loss</span></td>
<td align="center">77%</td>
<td align="center">72%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Cramps</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">73%</td>
<td align="center">68%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td align="center">63%</td>
<td align="center">65%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span></td>
<td align="center">50%</td>
<td align="center">55%</td>
</tr>
<tr>
<td align="left">Dermatologic</td>
<td align="center">46%</td>
<td align="center">40%</td>
</tr>
<tr>
<td align="left">Mental Status</td>
<td align="center">41%</td>
<td align="center">34%</td>
</tr>
<tr>
<td align="left">Pulmonary-Clinical</td>
<td align="center">39%</td>
<td align="center">39%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (not elsewhere classified)</td>
<td align="center">26%</td>
<td align="center">28%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">20%</td>
<td align="center">24%</td>
</tr>
<tr>
<td align="left">Cardiac-Clinical</td>
<td align="center">16%</td>
<td align="center">24%</td>
</tr>
<tr>
<td align="left">Neurologic-Peripheral Nerves</td>
<td align="center">7%</td>
<td align="center">9%</td>
</tr>
<tr>
<td align="left">Pulmonary <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></td>
<td align="center">2%</td>
<td align="center">4%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span></td>
<td align="center">4%</td>
<td align="center">5%</td>
</tr>
<tr class="Last">
<td align="left">Cerebellar</td>
<td align="center">4%</td>
<td align="center">4%</td>
</tr>
</tbody>
</table>
<p>The duration of <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> and incidence of <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> were greater on the IDR arm than the DNR arm, especially during consolidation in some U.S. controlled trials (see <a href="#CS">CLINICAL STUDIES</a>).</p>
<p>The following information reflects experience based on U.S. controlled clinical trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is the major toxicity associated with idarubicin therapy, but this effect of the drug is required in order to eradicate the leukemic clone. During the period of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, patients are at risk of developing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which may be life-threatening or fatal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were reported frequently, but were severe (equivalent to WHO Grade 4) in less than 5% of patients. Severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> with perforation has been reported rarely. The risk of perforation may be increased by instrumental intervention. The possibility of perforation should be considered in patients who develop severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and appropriate steps for diagnosis and management should be taken.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Dermatologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> was reported frequently and dermatologic reactions including generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and a bullous erythrodermatous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the palms and soles have occurred. The dermatologic reactions were usually attributed to concomitant antibiotic therapy. Local reactions including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> at the injection site have been reported. Recall of <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> due to prior radiotherapy has occurred with idarubicin administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Hepatic and Renal</h2>
<p class="First">Changes in hepatic and renal function tests have been observed. These changes were usually transient and occurred in the setting of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and while patients were receiving potentially hepatotoxic and nephrotoxic antibiotics and antifungal agents. Severe changes in renal function (equivalent to WHO Grade 4) occurred in no more than 1% of patients, while severe changes in hepatic function (equivalent to WHO Grade 4) occurred in less than 5% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Cardiac</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> (frequently attributed to <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>), serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and asymptomatic declines in LVEF have been reported in patients undergoing induction therapy for AML. Myocardial insufficiency and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> were usually reversible and occurred in the setting of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and aggressive intravenous fluid administration. The events were reported more frequently in patients over age 60 years and in those with pre-existing cardiac disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no known antidote to idarubicin. Two cases of fatal overdosage in patients receiving therapy for AML have been reported. The doses were 135 mg/m<span class="Sup">2</span> over 3 days and 45 mg/m<span class="Sup">2</span> of idarubicin and 90 mg/m<span class="Sup">2</span> of daunorubicin over a three day period.</p>
<p>It is anticipated that overdosage with idarubicin will result in severe and prolonged <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and possibly in increased severity of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>.  Adequate supportive care including platelet transfusions, antibiotics and symptomatic treatment of <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> is required. The effect of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> on cardiac function is not fully known, but severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> occurred in 1 of the 2 patients exposed. It is anticipated that very high doses of idarubicin may cause acute cardiac toxicity and may be associated with a higher incidence of delayed <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
<p>Disposition studies with idarubicin in patients undergoing dialysis have not been carried out. The profound multicompartment behavior, extensive extravascular distribution and tissue binding, coupled with the low unbound fraction available in the plasma pool make it unlikely that therapeutic efficacy or toxicity would be altered by conventional  peritoneal or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">(See <a href="#WARNINGS">WARNINGS</a>)</span></p>
<p>For induction therapy in adult patients with AML the following dose schedule is recommended:</p>
<p>IDAMYCIN PFS Injection 12 mg/m<span class="Sup">2</span> daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m<span class="Sup">2</span> daily by continuous infusion for 7 days or as cytarabine 25 mg/m<span class="Sup">2</span> intravenous bolus followed by cytarabine 200 mg/m<span class="Sup">2</span> daily for 5 days continuous infusion. In patients with unequivocal evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> after the first induction course, a second course may be administered. Administration of the second course should be delayed in patients who experience severe <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. In patients with hepatic and/or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a dose reduction of IDAMYCIN PFS should be considered. IDAMYCIN PFS should not be administered if the bilirubin level exceeds 5 mg%. (See <a href="#WARNINGS">WARNINGS</a>.)</p>
<p>The benefit of consolidation in prolonging the duration of remissions and survival is not proven. There is no consensus regarding optional regimens to be used for consolidation. (See <a href="#CS">CLINICAL STUDIES</a> for doses used in U.S. Clinical studies.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Preparation and Administration Precautions</h2>
<p class="First">Caution in handling the solution must be exercised as <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> associated with IDAMYCIN PFS may occur. Skin accidentally exposed to IDAMYCIN PFS should be washed thoroughly with soap and water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.</p>
<p>Care in the administration of IDAMYCIN PFS will reduce the chance of perivenous infiltration. It may also decrease the chance of local reactions such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and erythematous streaking. During intravenous administration of IDAMYCIN PFS <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> may occur with or without an accompanying <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> even if blood returns well on <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of the infusion needle. If any signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> have occurred, the injection or infusion should be immediately terminated and restarted in another vein. If it is known or suspected that subcutaneous <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> has occurred, it is recommended that intermittent ice packs (1/2 hour immediately, then 1/2 hour 4 times per day for 3 days) be placed over the area of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> and that the affected extremity be elevated. Because of the progressive nature of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> reactions, the area of injection should be frequently examined and plastic surgery consultation obtained early if there is any sign of a local reaction such as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or vesication. If ulceration begins or there is severe persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, early wide excision of the involved area should be considered.</p>
<p>IDAMYCIN PFS should be administered slowly (over 10 to 15 minutes) into the tubing of a freely running intravenous infusion of Sodium Chloride Injection, USP (0.9%) or 5% Dextrose Injection, USP. The tubing should be attached to a Butterfly needle or other suitable device and inserted preferably into a large vein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Incompatibility</h2>
<p class="First">Unless specific compatibility data are available, IDAMYCIN PFS should not be mixed with other drugs. Precipitation occurs with heparin. Prolonged contact with any solution of an alkaline pH will result in degradation of the drug.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and containers permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>Handling and Disposal</h1>
<p class="First">Procedures for handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.<span class="Sup">1–8</span> There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">IDAMYCIN PFS Injection (idarubicin hydrochloride injection)</p>
<p>Single Dose Cytosafe™ Vials: Sterile single use only, contains no preservative.<br>						NDC 0013-2576-91 5 mg/5 mL vial (1 mg/mL), single vials.<br>						NDC 0013-2586-91 10 mg/10 mL vial (1 mg/mL), single vials.<br>						NDC 0013-2596-91 20 mg/20 mL vial (1 mg/mL), single vials.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store under refrigeration 2º to 8ºC (36º to 46ºF), and protect from light. Retain in carton until time of use.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society. 1999: 32–41.</li>
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. Washington, DC; Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health; 1992. US Department of Health and Human Services, Public Health Service Publication NIH 92–2621.</li>
<li>AMA Council on Scientific Affairs. Guidelines for Handling Parenteral Antineoplastics. JAMA. 1985; 253:1590–1591.</li>
<li>National Study Commission on Cytotoxic Exposure - Recommendations for Handling Cytotoxic Agents. 1987. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.</li>
<li>Clinical Oncological Society of Australia: Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia. 1983; 1:426–428.</li>
<li>Jones RB, Frank R, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> T. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA Cancer J Clin.1983; 33: 258–263.</li>
<li>American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm. 1990; 47:1033–1049.</li>
<li>Controlling Occupational Exposure to Hazardous Drugs (OSHA Work-Practice Guidelines). Am J Health-Syst Pharm. 1996; 53: 1669–1685.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">LAB-0131-4.0<br>December 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Label</h1>
<p class="First">NDC 0013-2576-91</p>
<p>5 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">5 mg/5 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Carton</h1>
<p class="First">NDC 0013-2576-91</p>
<p><span class="Bold">5 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">5 mg/5 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/5 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Label</h1>
<p class="First">NDC 0013-2586-91</p>
<p>10 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">10 mg/10 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton</h1>
<p class="First">NDC 0013-2586-91</p>
<p><span class="Bold">10 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">10 mg/10 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg/20 mL Vial Label</h1>
<p class="First">NDC 0013-2596-91</p>
<p>20 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">20 mg/20 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg/20 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg/20 mL Vial Carton</h1>
<p class="First">NDC 0013-2596-91</p>
<p><span class="Bold">20 mL Single-Dose CYTOSAFE<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">Idamycin PFS<span class="Sup">®</span></span><br>idarubicin hydrochloride<br>injection</p>
<p><span class="Bold">20 mg/20 mL</span><br>(1 mg/mL)</p>
<p>For IV use only<br>Sterile, Isotonic Solution</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg/20 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&amp;name=idamycin-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IDAMYCIN PFS 		
					</strong><br><span class="contentTableReg">idarubicin hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0013-2576</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IDARUBICIN HYDROCHLORIDE</strong> (IDARUBICIN) </td>
<td class="formItem">IDARUBICIN HYDROCHLORIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0013-2576-91</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050734</td>
<td class="formItem">02/17/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IDAMYCIN PFS 		
					</strong><br><span class="contentTableReg">idarubicin hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0013-2586</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IDARUBICIN HYDROCHLORIDE</strong> (IDARUBICIN) </td>
<td class="formItem">IDARUBICIN HYDROCHLORIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0013-2586-91</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050734</td>
<td class="formItem">02/17/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IDAMYCIN PFS 		
					</strong><br><span class="contentTableReg">idarubicin hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0013-2596</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IDARUBICIN HYDROCHLORIDE</strong> (IDARUBICIN) </td>
<td class="formItem">IDARUBICIN HYDROCHLORIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0013-2596-91</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050734</td>
<td class="formItem">02/17/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Cork Limited</td>
<td class="formItem"></td>
<td class="formItem">988786778</td>
<td class="formItem">API MANUFACTURE(0013-2596, 0013-2586, 0013-2576)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer (Perth) Pty Limited</td>
<td class="formItem"></td>
<td class="formItem">757868963</td>
<td class="formItem">ANALYSIS(0013-2596, 0013-2586, 0013-2576), MANUFACTURE(0013-2596, 0013-2586, 0013-2576), PACK(0013-2596, 0013-2586, 0013-2576)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Antibioticos, SpA</td>
<td class="formItem"></td>
<td class="formItem">433371143</td>
<td class="formItem">API MANUFACTURE(0013-2596, 0013-2586, 0013-2576)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9ae27247-ea2b-44ea-bcf2-c766401042fe</div>
<div>Set id: 0a5a6d93-cc1e-4d7f-8da1-446c134503b3</div>
<div>Version: 6</div>
<div>Effective Time: 20150106</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
